Drug: Symproic (naldemedine)

Manufacturer: Collegium

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication: treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation

Disease: opioid-induced constipation (OIC)

Therapeutic Area: Gastroenterology

Enrollment Form Link: N/A

Phone Number: N/A

Fax Number: N/A

Product Website: symproic.com